Synap Biotech Inc.®
Unlocking Brain Repair
with Intranasal VHH Therapeutics
“From Stroke Survival to Recovery”
Vision:
We envision a future where surviving a stroke is only the beginning—and where recovery is transformed by therapies that help the brain repair itself.
Synap Biotech is developing intranasal VHH therapeutics designed to unlock neuroplasticity and restore function after stroke, with a platform that may ultimately extend to traumatic brain injury, CTE, and other neurological disorders.
Mission:
Our mission is to develop first-in-class intranasal VHH therapeutics that unlock the brain's natural capacity for repair and restore neurological function following stroke. By targeting the biological barriers that limit recovery, we are building a platform with the potential to transform treatment for traumatic brain injury, CTE, and other neurological disorders.